New Atlas

New approach shields memory from brain cancer radiotherapy

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...

Study identifies new approach to protect the brain during radiation therapy

While tremendous relief comes from successfully battling cancer, survivors can also experience cognitive impairments caused ...
Healthline

Understanding Medical Terminology for C3G and IgAN Kidney Diseases

C3G and IgAN are both rare forms of chronic kidney disease affecting the glomeruli, the kidney’s blood filters, but they arise from different immune system issues. Both conditions are immune-mediated ...
KXAN

Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD

CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...
Business Wire

Aviceda Completes Enrollment in Part 1 of the SIGLEC Phase 2/3 U.S. Clinical Trial; Initiation of Part 2 Imminent

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to ...
Forbes

A Closer Look At Protein-Based Therapies For Dry Macular Degeneration

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye, and it marks the second of a three-part series on dry ...
Medindia

Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD

Complement Therapeutics GmbH (CTx), a biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) ...